Natalie Tafel, PA, Weill Cornell Medicine, New York, NY, discusses the role of mutations in the treatment and prognosis of leukemia. Awareness of mutations in leukemia are important, especially in the context of minimal residual disease (MRD) measurements, as it can affect the eligibility and outcomes of patients receiving stem cell transplant. Mutations can additionally determine which targeted therapies a patient should receive. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.